Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study

Clicks: 293
ID: 115822
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Everolimus, letrozole, and metformin resulted in 50% CB and 28% OR in women with recurrent EEC. Progesterone receptor-positive tumors may have better response; validation studies are needed.See related commentary by Madariaga et al., p. 523.
Reference Key
pt2020clinicaleverolimus, Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Soliman PT;Westin SN;Iglesias DA;Fellman BM;Yuan Y;Zhang Q;Yates MS;Broaddus RR;Slomovitz BM;Lu KH;Coleman RL;;
Journal clinical cancer research : an official journal of the american association for cancer research
Year 2020
DOI
DOI not found
URL
https://www.pubmed.gov/31628143/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine comment pmid:31628143 pmc7002216 doi:10.1158/1078-0432.ccr-19-0471 pamela t soliman shannon n westin robert l coleman

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.